Lasmiditan
-
Sep
1
2011
Lasmiditan (COL-144) a Selective 5-HT1F agonist, is a rapid & effective oral treatment for acute migraine
Source: European Headache & Migraine Trust Ingernational Congress 2010
- Sep 1 2011
-
Jun
15
2010
Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial
Lasmiditan (COL-144; LY573144) is a novel, highly selective and potent agonist at 5-HT1F receptors that lacks vasoconstrictor activity. Preclinical and early clinical experiments predict acute ntimigraine efficacy of COL-144 that is mediated through a non-vascular, primarily neural, mechanism.
Source: Cephalalgia
- Jun 15 2010
-
Sep
11
2009
Prediction of Therapeutically Effective Dose of COL-144 Based on Relationship Between Plasma Concentrations and Headache Response
Source: 14th International Headache Congress; Philadelphia, PA